Dr. Bhisitkul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2402Fax+1 415-353-2713
Education & Training
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
- New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1992 - 1993
- Stanford University School of MedicineClass of 1992
Certifications & Licensure
- CA State Medical License 1998 - 2026
- MA State Medical License 1996 - 1999
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Start of enrollment: 2008 Apr 01
- Seven Year Update of Macular Degeneration Patients Start of enrollment: 2010 Dec 01
Publications & Presentations
PubMed
- 313 citationsSubgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.David S. Boyer, Andrew N. Antoszyk, Carl C. Awh, Robert B. Bhisitkul, Howard Shapiro
Ophthalmology. 2007-02-01 - 766 citationsSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).Soraya Rofagha, Robert B. Bhisitkul, David S. Boyer, Srinivas R. Sadda, Kang Zhang
Ophthalmology. 2013-11-01 - 147 citationsMacular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Study∗Robert B. Bhisitkul, Thais S. Mendes, Soraya Rofagha, Wayne T. A. Enanoria, David S. Boyer
American Journal of Ophthalmology. 2015-05-01
Press Mentions
- Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 23rd, 2023
- UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the EyeOctober 11th, 2022
- UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye DiseaseNovember 9th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: